37 results on '"Herrera-Camacho, Irma"'
Search Results
2. Development of Glycyrrhizinic Acid-Based Lipid Nanoparticle (LNP-GA) as An Adjuvant That Improves the Immune Response to Porcine Epidemic Diarrhea Virus Spike Recombinant Protein.
- Author
-
García-Cambrón, José Bryan, Cerriteño-Sánchez, José Luis, Lara-Romero, Rocío, Quintanar-Guerrero, David, Blancas-Flores, Gerardo, Sánchez-Gaytán, Brenda L., Herrera-Camacho, Irma, and Cuevas-Romero, Julieta Sandra
- Subjects
PORCINE epidemic diarrhea virus ,RECOMBINANT proteins ,NANOPARTICLES ,IMMUNE response ,RECOMBINANT viruses ,GIBBERELLINS - Abstract
Porcine epidemic diarrhea virus (PEDV) has affected the pork industry worldwide and during outbreaks the mortality of piglets has reached 100%. Lipid nanocarriers are commonly used in the development of immunostimulatory particles due to their biocompatibility and slow-release delivery properties. In this study, we developed a lipid nanoparticle (LNP) complex based on glycyrrhizinic acid (GA) and tested its efficacy as an adjuvant in mice immunized with the recombinant N-terminal domain (NTD) of porcine epidemic diarrhea virus (PEDV) spike (S) protein (rNTD-S). The dispersion stability analysis (Z-potential −27.6 mV) confirmed the size and charge stability of the LNP-GA, demonstrating that the particles were homogeneously dispersed and strongly anionic, which favors nanoparticles binding with the rNTD-S protein, which showed a slightly positive charge (2.11 mV) by in silico analysis. TEM image of LNP-GA revealed nanostructures with a spherical-bilayer lipid vesicle (~100 nm). The immunogenicity of the LNP-GA-rNTD-S complex induced an efficient humoral response 14 days after the first immunization (p < 0.05) as well as an influence on the cellular immune response by decreasing serum TNF-α and IL-1β concentrations, which was associated with an anti-inflammatory effect. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Phylogenetic and Molecular Analysis of the Porcine Epidemic Diarrhea Virus in Mexico during the First Reported Outbreaks (2013–2017).
- Author
-
Rivera-Benítez, José Francisco, Martínez-Bautista, Rebeca, González-Martínez, Raúl, De la Luz-Armendáriz, Jazmín, Herrera-Camacho, Irma, Rosas-Murrieta, Nora, Márquez-Valdelamar, Laura, and Lara, Rocio
- Subjects
PORCINE epidemic diarrhea virus ,VIRAL variation - Abstract
The characteristics of the whole PEDV genome that has circulated in Mexico from the first outbreak to the present are unknown. We chose samples obtained from 2013 to 2017 and sequenced them, which enabled us to identify the genetic variation and phylogeny in the virus during the first four years that it circulated in Mexico. A 99% identity was found among the analyzed pandemic strains; however, the 1% difference affected the structure of the S glycoprotein, which is essential for the binding of the virus to the cellular receptor. The S protein induces the most efficacious antibodies; hence, these changes in structure could be implicated in the clinical antecedents of the outbreaks. Antigenic changes could also help PEDV avoid neutralization, even in the presence of previous immunity. The characterization of the complete genome enabled the identification of three circulating strains that have a deletion in ORF1a, which is present in attenuated Asian vaccine strains. The phylogenetic analysis of the complete genome indicates that the first PEDV outbreaks in Mexico were caused by INDEL strains and pandemic strains related to USA strains; however, the possibility of the entry of European strains exists, which may have caused the 2015 and 2016 outbreaks. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Comparative Review of the State of the Art in Research on the Porcine Epidemic Diarrhea Virus and SARS-CoV-2, Scope of Knowledge between Coronaviruses.
- Author
-
Rosas-Murrieta, Nora H., Rodríguez-Enríquez, Alan, Herrera-Camacho, Irma, Millán-Pérez-Peña, Lourdes, Santos-López, Gerardo, and Rivera-Benítez, José F.
- Subjects
PORCINE epidemic diarrhea virus ,CORONAVIRUSES ,SARS-CoV-2 ,MIDDLE East respiratory syndrome ,SWINE farms ,SARS disease ,COVID-19 - Abstract
This review presents comparative information corresponding to the progress in knowledge of some aspects of infection by the porcine epidemic diarrhea virus (PEDV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) coronaviruses. PEDV is an alphacoronavirus of great economic importance due to the million-dollar losses it generates in the pig industry. PEDV has many similarities to the SARS-CoV-2 betacoronavirus that causes COVID-19 disease. This review presents possible scenarios for SARS-CoV-2 based on the collected literature on PEDV and the tools or strategies currently developed for SARS-CoV-2 that would be useful in PEDV research. The speed of the study of SARS-CoV-2 and the generation of strategies to control the pandemic was possible due to the knowledge derived from infections caused by other human coronaviruses such as severe acute respiratory syndrome (SARS) and middle east respiratory syndrome (MERS). Therefore, from the information obtained from several coronaviruses, the current and future behavior of SARS-CoV-2 could be inferred and, with the large amount of information on the virus that causes COVID-19, the study of PEDV could be improved and probably that of new emerging and re-emerging coronaviruses. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Neuraminidase activity of blue eye disease porcine rubulavirus: Specificity, affinity and inhibition studies
- Author
-
Santos-López, Gerardo, Borraz-Argüello, María T., Márquez-Domínguez, Luis, Flores-Alonso, Juan Carlos, Ramírez-Mendoza, Humberto, Priem, Bernard, Fort, Sébastien, Vallejo-Ruiz, Verónica, Reyes-Leyva, Julio, and Herrera-Camacho, Irma
- Published
- 2017
- Full Text
- View/download PDF
6. Production of an enzymatically active and immunogenic form of ectodomain of Porcine rubulavirus hemagglutinin-neuraminidase in the yeast Pichia pastoris
- Author
-
Cerriteño-Sánchez, José Luis, Santos-López, Gerardo, Rosas-Murrieta, Nora Hilda, Reyes-Leyva, Julio, Cuevas-Romero, Sandra, and Herrera-Camacho, Irma
- Published
- 2016
- Full Text
- View/download PDF
7. Transfection of influenza A virus nuclear export protein induces the expression of tumor necrosis factor alpha
- Author
-
Lara-Sampablo, Alejandra, Flores-Alonso, Juan Carlos, De Jesús-Ortega, Nereyda, Santos-López, Gerardo, Vallejo-Ruiz, Verónica, Rosas-Murrieta, Nora, Reyes-Carmona, Sandra, Herrera-Camacho, Irma, and Reyes-Leyva, Julio
- Published
- 2014
- Full Text
- View/download PDF
8. Structure-function analysis of two variants of mumps virus hemagglutinin-neuraminidase protein
- Author
-
Santos-Lopez, Gerardo, Scior, Thomas, del Transito Borraz-Arguello, Maria, Vallejo-Ruiz, Veronica, Herrera-Camacho, Irma, Tapia-Ramirez, Jose, and Reyes-Leyva, Julio
- Published
- 2009
9. Caracterizacion biologica de tres aislamientos naturales del Rubulavirus porcino (Mexico)
- Author
-
del Tránsito Borraz-Argüello, MarÃa, Santos-López, Gerardo, Vallejo-Ruiz, Verónica, Herrera-Camacho, Irma, and Reyes-Leyva, Julio
- Published
- 2008
10. Predicted 3D model of the M protein of Porcine Epidemic Diarrhea Virus and analysis of its immunogenic potential.
- Author
-
Rodríguez-Enríquez, Alan, Herrera-Camacho, Irma, Millán-Pérez-Peña, Lourdes, Reyes-Leyva, Julio, Santos-López, Gerardo, Rivera-Benítez, José Francisco, and Rosas-Murrieta, Nora Hilda
- Subjects
- *
PORCINE epidemic diarrhea virus , *PROTEIN models , *MEMBRANE proteins , *TYPE I interferons , *VIRAL envelope proteins , *T cells , *VIRAL proteins , *VIRAL envelopes - Abstract
The membrane protein M of the Porcine Epidemic Diarrhea Virus (PEDV) is the most abundant component of the viral envelope. The M protein plays a central role in the morphogenesis and assembly of the virus through protein interactions of the M-M, M-Spike (S) and M-nucleocapsid (N) type. The M protein is known to induce protective antibodies in pigs and to participate in the antagonistic response of the cellular antiviral system coordinated by the type I and type III interferon pathways. The 3D structure of the PEDV M protein is still unknown. The present work exposes a predicted 3D model of the M protein generated using the Robetta protocol. The M protein model is organized into a transmembrane and a globular region. The obtained 3D model of the PEDV M protein was compared with 3D models of the SARS-CoV-2 M protein created using neural networks and with initial machine learning-based models created using trRosetta. The 3D model of the present study predicted four linear B-cell epitopes (RSVNASSGTG and KHGDYSAVSNPSALT peptides are noteworthy), six discontinuous B-cell epitopes, forty weak binding and fourteen strong binding T-cell epitopes in the CV777 M protein. A high degree of conservation of the epitopes predicted in the PEDV M protein was observed among different PEDV strains isolated in different countries. The data suggest that the M protein could be a potential candidate for the development of new treatments or strategies that activate protective cellular mechanisms against viral diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. Biochemical characterization and structural prediction of a novel cytosolic leucyl aminopeptidase of the M17 family from Schizosaccharomyces pombe
- Author
-
Herrera-Camacho, Irma, Rosas-Murrieta, Nora H., Rojo-Domínguez, Arturo, Millán, Lourdes, Reyes-Leyva, Julio, Santos-López, Gerardo, and Suárez-Rendueles, Paz
- Published
- 2007
12. Modulation of apoptosis by V protein mumps virus
- Author
-
Herrera-Camacho Irma, Jurado Francisca, Reyes-Leyva Julio, Santos-López Gerardo, and Rosas-Murrieta Nora H
- Subjects
Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background The Urabe AM9 vaccine strain of mumps virus contains two variants of V protein: VWT (of HN-A1081 viral population) and VGly (of HN-G1081). The V protein is a promoting factor of viral replication by blocking the IFN antiviral pathway. Findings We studied the relationship between V protein variants and IFN-α2b-induced apoptosis. V proteins decrease activation of the extrinsic IFN-α2b-induced apoptotic pathway monitored by the caspase 8 activity, being the effect greater with the VWT protein. Both V proteins decrease the activity of caspase 9 of the intrinsic apoptotic pathway. In a system without IFN, the VWT and VGly proteins expression promotes activation of caspases 3 and 7. However, when the cellular system was stimulated with IFN-α, this activity decreased partially. TUNEL assay shows that for treatment with IFN-α and ibuprofen of cervical adenocarcinoma cells there is nuclear DNA fragmentation but the V protein expression reduces this process. Conclusions The reduction in the levels of caspases and DNA fragmentation, suggesting that V protein, particularly VWT protein of Urabe AM9 vaccine strain, modulates apoptosis. In addition, the VWT protein shows a protective role for cell proliferation in the presence of antiproliferative signals.
- Published
- 2011
- Full Text
- View/download PDF
13. Interaction of mumps virus V protein variants with STAT1-STAT2 heterodimer: experimental and theoretical studies
- Author
-
Reyes-Leyva Julio, Santos-López Gerardo, Palma-Ocampo Helen, Herrera-Camacho Irma, and Rosas-Murrieta Nora H
- Subjects
Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background Mumps virus V protein has the ability to inhibit the interferon-mediated antiviral response by inducing degradation of STAT proteins. Two virus variants purified from Urabe AM9 mumps virus vaccine differ in their replication and transcription efficiency in cells primed with interferon. Virus susceptibility to IFN was associated with insertion of a non-coded glycine at position 156 in the V protein (VGly) of one virus variant, whereas resistance to IFN was associated with preservation of wild-type phenotype in the V protein (VWT) of the other variant. Results VWT and VGly variants of mumps virus were cloned and sequenced from Urabe AM9 vaccine strain. VGly differs from VWT protein because it possesses an amino acid change Gln103Pro (Pro103) and the Gly156 insertion. The effect of V protein variants on components of the interferon-stimulated gene factor 3 (ISGF3), STAT1 and STAT2 proteins were experimentally tested in cervical carcinoma cell lines. Expression of VWT protein decreased STAT1 phosphorylation, whereas VGly had no inhibitory effect on either STAT1 or STAT2 phosphorylation. For theoretical analysis of the interaction between V proteins and STAT proteins, 3D structural models of VWT and VGly were predicted by comparing with simian virus 5 (SV5) V protein structure in complex with STAT1-STAT2 heterodimer. In silico analysis showed that VWT-STAT1-STAT2 complex occurs through the V protein Trp-motif (W174, W178, W189) and Glu95 residue close to the Arg409 and Lys415 of the nuclear localization signal (NLS) of STAT2, leaving exposed STAT1 Lys residues (K85, K87, K296, K413, K525, K679, K685), which are susceptible to proteasome degradation. In contrast, the interaction between VGly and STAT1-STAT2 heterodimer occurs in a region far from the NLS of STAT2 without blocking of Lys residues in both STAT1 and STAT2. Conclusions Our results suggest that VWT protein of Urabe AM9 strain of mumps virus may be more efficient than VGly to inactivate both the IFN signaling pathway and antiviral response due to differences in their finest molecular interaction with STAT proteins.
- Published
- 2010
- Full Text
- View/download PDF
14. Histone H3K9 and H3K14 acetylation at the promoter of the LGALS9 gene is associated with mRNA levels in cervical cancer cells.
- Author
-
Armenta‐Castro, Erick, Reyes‐Vallejo, Tania, Máximo‐Sánchez, Daniel, Herrera‐Camacho, Irma, López‐López, Gustavo, Reyes‐Carmona, Sandra, Conde‐Rodríguez, Ileana, Ramírez‐Díaz, Ivonne, Aguilar‐Lemarroy, Adriana, Jave‐Suárez, Luis Felipe, Milflores‐Flores, Lorena, Santos‐Lopez, Gerardo, Reyes‐Leyva, Julio, and Vallejo‐Ruiz, Verónica
- Subjects
MESSENGER RNA ,CERVICAL cancer ,CANCER cells ,PROMOTERS (Genetics) ,ACETYLATION ,HELA cells - Abstract
Galectin‐9 levels have been reported to be altered in several cancer types, but the mechanism that regulates the expression of Galectin‐9 has not been clarified. Galectin‐9 is encoded by the LGALS9 gene, which gives rise to eight mRNA variants. The aims of this study were: (a) to identify the mRNA variants of LGALS9, (b) to characterize CpG methylation and H3K9 and H3K14 histone acetylation at the promoter of the LGALS9 gene, and (c) to characterize the relationship between these modifications and LGALS9 expression level in cervical cancer cells. All mRNA variants were detected in HaCaT (nontumoural keratinocytes) and SiHa cells, and seven were observed in HeLa cells. The promoter region of LGALS9 contains eight CpG dinucleotides. No hypermethylation pattern related to low LGALS9 expression was identified in tumour cells. Chromatin immunoprecipitation analysis demonstrated higher acetylation of H3K9ac and H3K14ac in HaCaT cells, which was related to higher mRNA levels. The presence of the mRNA variants suggests that alternative splicing may regulate the expression of galectin‐9 isoforms. The results of this study suggest that histone acetylation, but not promoter CpG methylation, may be involved in the transcriptional regulation of the LGALS9 gene. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
15. Immunoinformatics approach for predicting epitopes in HN and F proteins of Porcine rubulavirus.
- Author
-
Siañez-Estrada, Luis I., Rivera-Benítez, José F., Rosas-Murrieta, Nora H., Reyes-Leyva, Julio, Santos-López, Gerardo, and Herrera-Camacho, Irma
- Subjects
EPITOPES ,RECOMBINANT proteins ,VACCINE development ,BINDING energy ,VACCINE effectiveness - Abstract
Porcine rubulavirus (PRV), which belongs to the family Paramyxoviridae, causes blue eye disease in pigs, characterized by encephalitis and reproductive failure in newborn and adult pigs, respectively. There is no effective treatment against PRV and no information on the effectiveness of the available vaccines. Continuous outbreaks have occurred in Mexico since the early 1980s, which have caused serious economic losses to pig producers. Vaccination can be used to control this disease. Searching for effective antigen candidates against PRV, we first sequenced the PAC1 F protein, then we used various immunoinformatics tools to predict antigenic determinants of B-cells and T-cells against the two glycoproteins of the virus (HN and F proteins). Finally, we used AutoDock Vina to determine the binding energies. We obtained the F gene sequence of a PRV strain collected in the early 1990s in Mexico and compared its amino acid profile with previous and more recent strains, obtaining an identity similarity of 97.78 to 99.26%. For the F proteins, seven linear B-cell epitopes, six conformational B-cell epitopes and twenty-nine T-cell MHC class I epitopes were predicted. For the HN proteins, sixteen linear B-cell epitopes, seven conformational B-cell epitopes and thirty-four T-cell MHC class I epitopes were predicted. The ATRSETDYY and AAYTTTTCF epitopes of the HN protein might be important for neutralizing the viral infection. We determined the in silico binding energy between the predicted epitopes on the F and HN proteins and swine MHC-I molecules. The binding energy of these epitopes ranged from -5.8 to -7.8 kcal/mol. The present study aimed to assess the use of HN and F proteins as antigens, either as recombinant proteins or as a series of peptides that could activate different responses of the immune system. This may help identify relevant immunogens, saving time and costs in the development of new vaccines or diagnostic tools. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
16. Antiviral and immunomodulatory effects of polyphenols on macrophages infected with dengue virus serotypes 2 and 3 enhanced or not with antibodies.
- Author
-
Jasso-Miranda, Carolina, Herrera-Camacho, Irma, Flores-Mendoza, Lilian Karem, Dominguez, Fabiola, Vallejo-Ruiz, Veronica, Sanchez-Burgos, Gilma Guadalupe, Pando-Robles, Victoria, Santos-Lopez, Gerardo, and Reyes-Leyva, Julio
- Subjects
ARBOVIRUS diseases ,DENGUE viruses ,IMMUNOGLOBULINS ,MACROPHAGES - Abstract
Background: There is a lack of specific antiviral therapy against dengue virus (DENV) in current use. Therefore, a great proportion of dengue cases progress to severe clinical forms due to a complex interplay between virus and host immune response. It has been hypothesized that heterotypic non-neutralizing antibodies enhance DENV infection in phagocytic cells, and this induces an inflammatory response that is involved in the pathogenesis of severe dengue. Purpose: To identify the antiviral and immunomodulatory effects of polyphenols on dengue virus infection. Methods: Human U937-DC-SIGN macrophages were infected with DENV serotypes 2 or 3 in the presence or not of enhancing antibody 4G2. Viral titers and the secretion of tumor necrosis factor-alpha, IL-6, IL-10 and interferon-alpha were analyzed timely. Results: DENV infection alone induced high production of IL-6 and TNF-α, but in the presence of 4G2 antibody, viral titers and TNF-α secretion were potentiated. Based on anti-inflammatory antecedents, the polyphenols curcumin, fisetin, resveratrol, apigenin, quercetin and rutin were tested for antiviral and immunomodulatory properties. Only quercetin and fisetin inhibited DENV-2 and DENV-3 infection in the absence or presence of enhancing antibody (>90%, p<0.001); they also inhibited TNF-α and IL-6 secretion (p<0.001). Conclusion: Quercetin and fisetin down-regulate the production of proinflammatory cytokines induced by DENV infection enhanced by antibodies a mechanism involved in severe dengue. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
17. Breast Cancer Subtypes Present a Differential Production of Reactive Oxygen Species (ROS) and Susceptibility to Antioxidant Treatment.
- Author
-
Sarmiento-Salinas, Fabiola Lilí, Delgado-Magallón, Alam, Montes-Alvarado, José Benito, Ramírez-Ramírez, Dalia, Flores-Alonso, Juan Carlos, Cortés-Hernández, Paulina, Reyes-Leyva, Julio, Herrera-Camacho, Irma, Anaya-Ruiz, Maricruz, Pelayo, Rosana, Millán-Pérez-Peña, Lourdes, and Maycotte, Paola
- Subjects
BREAST cancer ,TRIPLE-negative breast cancer ,REACTIVE oxygen species ,THERAPEUTICS ,CELL lines ,CELL metabolism - Abstract
Due to their crucial role in cell metabolism and homeostasis, alterations in mitochondrial biology and function have been related to the progression of diverse diseases including cancer. One of the consequences associated to mitochondrial dysfunction is the production of reactive oxygen species (ROS). ROS are known to have a controversial role during cancer initiation and progression and although several studies have tried to manipulate intracellular ROS levels using antioxidants or pro-oxidation conditions, it is not yet clear how to target oxidation for cancer therapy. In this study, we found differences in mitochondrial morphology in breast cancer cells when compared to a non-tumorigenic cell line and differences in mitochondrial function among breast cancer subtypes when exploring gene-expression data from the TCGA tumor dataset. Interestingly, we found increased ROS levels in triple negative breast cancer (TNBC) cell lines and a dependency on ROS for survival since antioxidant treatment induced cell death in TNBC cells but not in an estrogen receptor positive (ER+) cell line. Moreover, we identified the mitochondria as the main source of ROS in TNBC cell lines. Our results indicate a potential use for ROS as a target for therapy in the TNBC subtype which currently has the worst prognosis among all breast cancers and remains as the only breast cancer subtype which lacks a targeted therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
18. Upregulation of the Suppressors of Cytokine Signaling 1 and 3 Is Associated with Arrest of Phosphorylated-STAT1 Nuclear Importation and Reduced Innate Response in Denguevirus-Infected Macrophages.
- Author
-
Estrada-Jiménez, Tania, Millán-Pérez Peña, Lourdes, Flores-Mendoza, Lilian, Sedeño-Monge, Virginia, Santos-López, Gerardo, Rosas-Murrieta, Nora, Reyes-Carmona, Sandra, Terán-Cabanillas, Eli, Hernández, Jesus, Herrera-Camacho, Irma, Vallejo-Ruiz, Verónica, and Reyes-Leyva, Julio
- Published
- 2016
- Full Text
- View/download PDF
19. Chronic Cadmium Exposure Lead to Inhibition of Serum and Hepatic Alkaline Phosphatase Activity in Wistar Rats.
- Author
-
Treviño, Samuel, Andrade‐García, Alejandra, Herrera Camacho, Irma, León‐Chavez, Bertha Alicia, Aguilar‐Alonso, Patricia, Flores, Gonzalo, and Brambila, Eduardo
- Abstract
ABSTRACT Alkaline phosphatase (ALP) activity in the serum and liver from rats administered with cadmium (Cd) in drinking water was studied. After metal administration, Cd showed a time-dependent accumulation in the liver, meanwhile metallothionein had a maximum increase at 1 month, remaining in this level until the end of the study. On the other hand, serum and liver ALP activity was decreased after 3 months exposure. To determine if Cd produced an inhibition on enzyme, apo-ALP prepared from both nonexposed and exposed rats was reactivated with Zn, showing 60% more activity as compared with the enzyme isolated from nonexposed rats. In vitro assays showed that Cd-ALP was partially reactivated with Zn; however, in the presence of cadmium, Zn-ALP was completely inhibited. Kinetic studies indicate a noncompetitive inhibition by Cd; these results suggest that Cd can substitute Zn, and/or Cd can interact with nucleophilic ligands essential for the enzymatic activity. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
20. Interferon lambda inhibits dengue virus replication in epithelial cells.
- Author
-
Palma-Ocampo, Helen K., Flores-Alonso, Juan C., Vallejo-Ruiz, Verónica, Reyes-Leyva, Julio, Flores-Mendoza, Lilian, Herrera-Camacho, Irma, Rosas-Murrieta, Nora H., and Santos-López, Gerardo
- Subjects
DENGUE ,EPITHELIAL cells ,INTERFERONS ,CYTOKINES ,MESSENGER RNA - Abstract
Background: In viral disease, infection is controlled at the cellular level by type I interferon (IFN-I), but dengue virus (DENV) has the ability to inhibit this response. Type III interferon, also known as lambda IFN (IFN-III or IFN-λ), is a complementary pathway to the antiviral response by IFN-I. This work analyzed the IFN-λ (IFN-III) mediated antiviral response against DENV serotype 2 (DENV-2) infection. Methods: Dengue fever patients were sampled to determine their IFN-λ levels by ELISA. To study the IFN-λ response during DENV infection we selected the epithelial cell line C33-A, and we demonstrated that it is permissive to DENV-2 infection. The effect of IFN-λ on virus replication was determined in these cells, in parallel to the expression of IFN-stimulated genes (ISGs), and Suppressor of Cytokine Signaling (SOCS), genes measured by RT-qPCR. Results: We found increased (~1.8 times) serological IFN-λ in dengue fever patients compared to healthy blood donors. IFN-λ inhibited DENV-2 replication in a dose-dependent manner in vitro. The reduction of viral titer corresponded with increased ISG mRNA levels (MX1 and OAS1), with the highest inhibition occurring at ISG's peak expression. Presence of IFN-negative regulators, SOCS1 and SOCS3, during DENV-2 infection was associated with reduced IFN-λ1 expression. Conclusions: Evidence described here suggests that IFN-λ is a good candidate inhibitor of viral replication in dengue infection. Mechanisms for the cellular and organismal interplay between DENV and IFN- λ need to be further studied as they could provide insights into strategies to treat this disease. Furthermore, we report a novel epithelial model to study dengue infection in vitro. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
21. Modulation of apoptosis by V protein mumps virus.
- Author
-
Rosas-Murrieta, Nora H., Santos-López, Gerardo, Reyes-Leyva, Julio, Jurado, Francisca Sosa, and Herrera-Camacho, Irma
- Subjects
MUMPS vaccines ,APOPTOSIS ,VIRAL proteins ,ADENOCARCINOMA ,CELL death - Abstract
Background: The Urabe AM9 vaccine strain of mumps virus contains two variants of V protein: VWT (of HN-A1081 viral population) and VGly (of HN-G1081). The V protein is a promoting factor of viral replication by blocking the IFN antiviral pathway. Findings: We studied the relationship between V protein variants and IFN-α2b-induced apoptosis. V proteins decrease activation of the extrinsic IFN-α2b-induced apoptotic pathway monitored by the caspase 8 activity, being the effect greater with the VWT protein. Both V proteins decrease the activity of caspase 9 of the intrinsic apoptotic pathway. In a system without IFN, the VWT and VGly proteins expression promotes activation of caspases 3 and 7. However, when the cellular system was stimulated with IFN-α, this activity decreased partially. TUNEL assay shows that for treatment with IFN-α and ibuprofen of cervical adenocarcinoma cells there is nuclear DNA fragmentation but the V protein expression reduces this process. Conclusions: The reduction in the levels of caspases and DNA fragmentation, suggesting that V protein, particularly VWT protein of Urabe AM9 vaccine strain, modulates apoptosis. In addition, the VWT protein shows a protective role for cell proliferation in the presence of antiproliferative signals. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
22. Interaction of mumps virus V protein variants with STAT1-STAT2 heterodimer: experimental and theoretical studies.
- Author
-
Rosas-Murrieta, Nora H., Herrera-Camacho, Irma, Palma-Ocampo, Helen, Santos-López, Gerardo, and Reyes-Leyva, Julio
- Subjects
- *
MUMPS , *INTERFERONS , *VIRAL replication , *PHENOTYPES , *PROTEINS - Abstract
Background: Mumps virus V protein has the ability to inhibit the interferon-mediated antiviral response by inducing degradation of STAT proteins. Two virus variants purified from Urabe AM9 mumps virus vaccine differ in their replication and transcription efficiency in cells primed with interferon. Virus susceptibility to IFN was associated with insertion of a non-coded glycine at position 156 in the V protein (VGly) of one virus variant, whereas resistance to IFN was associated with preservation of wild-type phenotype in the V protein (VWT) of the other variant. Results: VWT and VGly variants of mumps virus were cloned and sequenced from Urabe AM9 vaccine strain. VGly differs from VWT protein because it possesses an amino acid change Gln103Pro (Pro103) and the Gly156 insertion. The effect of V protein variants on components of the interferon-stimulated gene factor 3 (ISGF3), STAT1 and STAT2 proteins were experimentally tested in cervical carcinoma cell lines. Expression of VWT protein decreased STAT1 phosphorylation, whereas VGly had no inhibitory effect on either STAT1 or STAT2 phosphorylation. For theoretical analysis of the interaction between V proteins and STAT proteins, 3D structural models of VWT and VGly were predicted by comparing with simian virus 5 (SV5) V protein structure in complex with STAT1-STAT2 heterodimer. In silico analysis showed that VWT-STAT1-STAT2 complex occurs through the V protein Trp-motif (W174, W178, W189) and Glu95 residue close to the Arg409 and Lys415 of the nuclear localization signal (NLS) of STAT2, leaving exposed STAT1 Lys residues (K85, K87, K296, K413, K525, K679, K685), which are susceptible to proteasome degradation. In contrast, the interaction between VGly and STAT1-STAT2 heterodimer occurs in a region far from the NLS of STAT2 without blocking of Lys residues in both STAT1 and STAT2. Conclusions: Our results suggest that VWT protein of Urabe AM9 strain of mumps virus may be more efficient than VGly to inactivate both the IFN signaling pathway and antiviral response due to differences in their finest molecular interaction with STAT proteins. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
23. Differential sensitivity to interferon influences the replication and transcription of Urabe AM9 mumps virus variants in nerve cells
- Author
-
Rosas-Murrieta, Nora, Herrera-Camacho, Irma, Vallejo-Ruiz, Verónica, Millán-Pérez-Peña, Lourdes, Cruz, Carlos, Tapia-Ramírez, José, Santos-López, Gerardo, and Reyes-Leyva, Julio
- Subjects
- *
ANTINEOPLASTIC agents , *ANTIVIRAL agents , *PREVENTIVE medicine , *GLYCOPROTEINS - Abstract
Abstract: Urabe AM9 mumps virus vaccine causes post-vaccination meningitis. Two variants of Urabe AM9 virus differ in their replication efficiency in human nerve cells, HN-A1081 variant being more neurotropic than HN-G1081. The effect of interferon (IFN) on viral replication and transcription was analyzed. Priming of nerve cells with IFN reduced more significantly the replication of HN-G1081 variant (from 102.5 to 101.3 TCID50) than that of HN-A1081 (from 103.5 to 102.6 TCID50). IFN-priming also reduced the transcription of HN-G1081 genes, but not of HN-A1081. The effect of viral infection on the transcription of cellular IFN responsive genes was analyzed. HN-A1081 virus reduced the transcription of STAT1, STAT2, p48 and MxA in both unprimed and IFN-primed cells; whereas HN-G1081 virus just reduced MxA transcription. Since rubulavirus V protein inhibits IFN signaling, the V mRNA was cloned and sequenced, finding that HN-G1081 but not HN-A1081 presented three extra G in the P/V edition site, producing the insertion of Gly156 in the V protein. Our results suggest that the replication efficiency of Urabe AM9 mumps virus variants is influenced by their sensitivity to interferon and their capacity to reduce the antiviral response. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
24. Aminopeptidase yscCo-II: a new cobalt-dependent aminopeptidase from yeast-purification and biochemical characterization.
- Author
-
Herrera-Camacho, Irma, Morales-Monterrosas, Rosalva, and Quiróz-Alvarez, Rubén
- Published
- 2000
- Full Text
- View/download PDF
25. Five Novel Non-Sialic Acid-Like Scaffolds Inhibit In Vitro H1N1 and H5N2 Neuraminidase Activity of Influenza a Virus.
- Author
-
Márquez-Domínguez, Luis, Reyes-Leyva, Julio, Herrera-Camacho, Irma, Santos-López, Gerardo, Scior, Thomas, and Costa, Giosuè
- Subjects
INFLUENZA A virus ,INFLUENZA A virus, H1N1 subtype ,NEURAMINIDASE ,AVIAN influenza ,SIALIC acids ,SMALL molecules - Abstract
Neuraminidase (NA) of influenza viruses enables the virus to access the cell membrane. It degrades the sialic acid contained in extracellular mucin. Later, it is responsible for releasing newly formed virions from the membrane of infected cells. Both processes become key functions within the viral cycle. Therefore, it is a therapeutic target for research of the new antiviral agents. Structure–activity relationships studies have revealed which are the important functional groups for the receptor–ligand interaction. Influenza virus type A NA activity was inhibited by five scaffolds without structural resemblance to sialic acid. Intending small organic compound repositioning along with drug repurposing, this study combined in silico simulations of ligand docking into the known binding site of NA, along with in vitro bioassays. The five proposed scaffolds are N-acetylphenylalanylmethionine, propanoic 3-[(2,5-dimethylphenyl) carbamoyl]-2-(piperazin-1-yl) acid, 3-(propylaminosulfonyl)-4-chlorobenzoic acid, ascorbic acid (vitamin C), and 4-(dipropylsulfamoyl) benzoic acid (probenecid). Their half maximal inhibitory concentration (IC
50 ) was determined through fluorometry. An acidic reagent 2′-O-(4-methylumbelliferyl)-α-dN-acetylneuraminic acid (MUNANA) was used as substrate for viruses of human influenza H1N1 or avian influenza H5N2. Inhibition was observed in millimolar ranges in a concentration-dependent manner. The IC50 values of the five proposed scaffolds ranged from 6.4 to 73 mM. The values reflect a significant affinity difference with respect to the reference drug zanamivir (p < 0.001). Two compounds (N-acetyl dipeptide and 4-substituted benzoic acid) clearly showed competitive mechanisms, whereas ascorbic acid reflected non-competitive kinetics. The five small organic molecules constitute five different scaffolds with moderate NA affinities. They are proposed as lead compounds for developing new NA inhibitors which are not analogous to sialic acid. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
26. Swine health: history, challenges and prospects.
- Author
-
Rivera-Benitez, José Francisco, De la Luz-Annendáriz, Jazmín, Gómez-Núñez, Luis, Diosdado Vargas, Fernando, Socci Escatell, Guadalupe, Ramírez-Medina, Elizabeth, Velázquez-Salinas, Lauro, Ramírez-Mendoza, Humberto, Coba Ayala, Maria Antonia, Tufíño-Loza, Catalina, Macias García, Marta, Carrera-Aguirre, Víctor, Martínez-Bautista, Rebeca, Martínez-Mercado, María José, Santos-López, Gerardo, Herrera-Camacho, Irma, Siañez-Estrada, Ignacio, and Zapata Moreno, Manuel
- Subjects
- *
SWINE , *COMMUNICABLE diseases , *ANIMAL health , *SWINE farms , *RESEARCH institutes , *LABORATORY animals - Abstract
In swine production systems, one of the critical points that must be strictly attended to is the health of the pigs. Health is a structural component of animal welfare and reflects an optimal state of the animals, which has a direct impact on a higher productive performance and better development conditions. Infectious diseases are one of the greatest threats to the health of pigs and can cause losses of up to 100 % of production; therefore, it requires constant attention and continuous monitoring by the veterinarian and producers, in perfect coordination with the official health authorities. Currently, the implementation of best practices in the production chain is of interest to both producers and consumers. The control of infectious diseases requires collaboration between the various actors in the environment and must be considered a public good, since their negative repercussions can range from the local to the global level. This review will address the main infectious diseases that endanger swine health, their impact, the main contributions made by the National Institute for Research in Forestry, Agriculture and Livestock (INIFAP) in its 35 years of life, mainly at the National Center for Disciplinary Research in Animal Health and Safety (CENID-SAI), formerly known as the emblematic CENID-Microbiologia or Palo Alto. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
27. Caracterización biológica de tres aislamientos naturales del Rubulavirus porcino (México).
- Author
-
Borraz-Argüello, María del Tránsito, Santos-López, Gerardo, Vallejo-Ruiz, Verónica, Herrera-Camacho, Irma, and Reyes-Leyva, Julio
- Subjects
- *
DISEASES , *SWINE , *NEURAMINIDASE , *GLYCOSIDASES - Abstract
Porcine rubulavirus (PoRV) produces a neurological and reproductive syndrome in pigs called the blue-eye disease, known only from Mexico. Several isolates were grouped by the main symptoms presented during outbreaks: a) neurotropic in piglets, b) broadly neurotropic in piglets and gonadotropic in adults, and c) gonadotropic in adults. We studied some biological properties of three strains, which fall in one of each virus group: La Piedad Michoacán (LPM) and Producción Animal Cerdos 1 (PAC1) and 3 (PAC3), respectively. The analyzed viral properties are mainly related with the trans-membrane hemagglutinin-neuraminidase (HN) and fusion (F) proteins, such as cytopathic effect, hemolysis, hemagglutinating (HA) and neuraminidase (NA) activities. In the infection assays PAC1 strain presented the highest fusogenicity level; however, the most cytolytic strain was PAC3. In addition, HA and NA activities and viral genome of PAC3 strain was detected in supernatants during cell infection earlier than in the other two strains, which shows that PAC3 virions release from the host cell earlier than LPM and PAC1. Experimental determination in purified viruses shows that PAC3 presented a higher HA and NA activities; however, PAC1 shows other interesting properties, such as a high thermostability of HN and differences about substrate profile respect to LPM and PAC3. Our data suggest that NA activity is associated with the virulence of RVP. [ABSTRACT FROM AUTHOR]
- Published
- 2008
28. Purification of the Porcine rubulavirus attachment protein by liquid isoelectric focusing
- Author
-
Santos-López, Gerardo, Flores, Esmeralda, Baños, Rocío, Herrera-Camacho, Irma, and Reyes-Leyva, Julio
- Subjects
- *
ISOELECTRIC focusing , *ELECTROPHORESIS , *PROTEINS , *SIALIC acids - Abstract
Porcine rubulavirus (PoRV) is an emerging virus responsible for meningoencephalitis, respiratory distress, and reproductive alterations in pigs. The hemagglutinin–neuraminidase (HN) glycoprotein is the most exposed and antigenic of the virus proteins. HN plays central roles in PoRV infection; i.e., it recognizes sialic acid-containing cell receptors that mediate virus attachment and penetration; in addition, its neuraminidase (sialic acid hydrolysis) activity has been proposed to be a virulence factor. So, HN is an ideal target for therapeutic treatment and prevention of this viral infection. This work describes a simple, fast, and sensitive method to purify the active form of HN protein based on its isoelectric point. HN was purified at a pH of 4.4, at which a single protein band of 66 kDa was observed on SDS–PAGE. Pure HN showed a maximal enzymatic activity at pH 3.5 and 37 °C using bovine fetuin as substrate. However, it retains circa 80% of its activity at a wide temperature range from 30 to 55 °C. We also describe improvements of neuraminidase determination method, which permits analysis in a microplate spectrophotometer, thereby increasing the sensitivity and reducing the costs of valuable reagents and biological samples. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
29. OX40 agonists for cancer treatment: a patent review.
- Author
-
Cebada J, Perez-Santos M, Bandala C, Lara-Padilla E, Herrera-Camacho I, Rosas-Murrieta NH, Millán-Pérez Peña L, Monjaraz E, Flores A, and Anaya-Ruiz M
- Subjects
- Animals, Drug Development, Humans, Immunotherapy, Neoplasms immunology, Neoplasms pathology, Patents as Topic, Receptors, OX40 immunology, Antineoplastic Agents pharmacology, Neoplasms drug therapy, Receptors, OX40 agonists
- Abstract
Introduction: OX40 is an immune checkpoint in cancer and its presence in cancer is a good prognosis, making it a highly relevant target for the development of new immunotherapies., Areas Covered: The patent literature reveals vital information on new trends in cancer therapies. The authors used the patent databases of the six major patent offices in the world: United States Patent and Trademark Office, European Patent Office, World Intellectual Property Organization, Japan Patent Office, State Office of Intellectual Property of China and Korean Intellectual Property Office, to generate a panorama of patents related to OX40 agonists. Specific patents have been grouped into innovative patents and adoption patents., Expert Opinion: An increasing trend in the development of OX40 agonists in cancer, particularly in the years 2018 and 2019. United States was the leader in generating patents, followed by China and England. Major pharmaceutical companies have at least one anti-OX40 agonist, MEDI6469 and MEDI-0562 (AstraZeneca), PF-04518600 (Pfizer), GSK3174998 (GlaxoSmithKline), BMS-986,178 (Bristol-Myers Squibb) and MOXR0916 (Roche), which represent 68% of clinical trials conducted with OX40 agonists.
- Published
- 2021
- Full Text
- View/download PDF
30. Colon carcinoma treatment using bispecific anti-GITR/CTLA-4 antibodies: a patent evaluation of WO2018091739.
- Author
-
Millán-Pérez Peña L, Martin PS, Herrera-Camacho I, Bandala C, and Anaya-Ruiz M
- Subjects
- Animals, Antibodies, Bispecific pharmacology, CHO Cells, CTLA-4 Antigen immunology, Colonic Neoplasms immunology, Cricetulus, Glucocorticoid-Induced TNFR-Related Protein immunology, Humans, Mice, Patents as Topic, T-Lymphocytes immunology, Treatment Outcome, Antibodies, Bispecific administration & dosage, Colonic Neoplasms therapy, Immunotherapy methods
- Abstract
Introduction : GITR is a receptor that increases the activation of T lymphocytes against tumor cells. There is a great need to discover and develop new therapies focused on activating GITR to increase the immune response in various types of cancer. The authors of WO2018091739 patent propose a method to eradicate cancer by using bispecific anti-GITR/anti-CTLA-4 antibodies. Areas covered : WO2018091739 patent describes anti-GITR/anti-CTLA-4 antibodies, pharmaceutical composition that contains it, and their application for cancer treatment, particularly colon carcinoma. Anti-GITR/anti-CTLA-4 antibodies are used at a dosage of 0.0003-3 mg antibody/kg patient weight and is suspended in an isotonic solution consisting of sodium phosphate, sucrose, NaCl, and polysorbate 80. Expert opinion : WO2018091739 only demonstrates that bispecific antibodies activate T cells, an antibody-dependent cellular cytotoxicity of CHO cells, and tumor inhibition in murine models of colon carcinoma. There are no clinical trials that show that treatment with bispecific antibodies can induce an antitumor response in cancer patients.
- Published
- 2020
- Full Text
- View/download PDF
31. Cancer combinatorial immunotherapy using etigilimab and nivolumab: a patent evaluation of WO2018102536.
- Author
-
Perez-Santos M, Anaya-Ruiz M, Herrera-Camacho I, Rosas-Murrieta NH, and Millán-Pérez Peña L
- Subjects
- Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antineoplastic Combined Chemotherapy Protocols pharmacology, B7-H1 Antigen antagonists & inhibitors, Humans, Neoplasms immunology, Patents as Topic, Programmed Cell Death 1 Receptor antagonists & inhibitors, Receptors, Immunologic antagonists & inhibitors, Immunotherapy methods, Neoplasms therapy, Nivolumab administration & dosage
- Abstract
Introduction : TIGIT is an inhibitory receptor expressed by lymphocytes that suppresses the immune response against tumor cells. There is a great need to discover and develop new therapies focused on inhibiting the action of TIGIT and consequently improving the immune response in the various types of cancer. Authors of WO2018102536 patent propose a method to eradicate cancer utilizes anti-TIGIT antibody, etigilimab, in combination with anti-PD-1/PD-L1 antibody, nivolumab. Areas covered : WO2018102536 patent describes a method of cancer combinatorial treatment consisting of the utilization of either a pharmaceutical cocktail containing anti-TIGIT and an anti-PD-L1 antibody. Expert opinion : The results of the clinical trials only support trials regarding the tolerability of therapy with etigilimab, but does not show data related to the combined use of etigilimab and nivolumab.
- Published
- 2020
- Full Text
- View/download PDF
32. Bispecific anti-OX40/CTLA-4 antibodies for advanced solid tumors: a patent evaluation of WO2018202649.
- Author
-
Perez-Santos M, Anaya-Ruiz M, Herrera-Camacho I, Millán-Pérez Peña L, and Rosas-Murrieta NH
- Subjects
- Animals, Antibodies, Bispecific immunology, CTLA-4 Antigen immunology, Drug Synergism, Drug Therapy, Combination, Humans, Molecular Targeted Therapy, Neoplasms immunology, Neoplasms pathology, Patents as Topic, Receptors, OX40 immunology, Tumor Microenvironment immunology, Antibodies, Bispecific administration & dosage, Immunotherapy methods, Neoplasms drug therapy
- Abstract
Introduction : OX40 is a potent costimulatory receptor of the immune response in various types of cancer and has been used as a target for the generation of agonists of its function. Authors of WO2018202649 patent propose a method to eradicate cancer using a bispecific antibodies against OX40/CTLA-4. Areas covered : WO2018202649 patent describes several bispecific antibodies capable of specifically binding to OX40 and CTLA-4 that target regulatory T cells in the tumor microenvironment. Expert opinion : WO2018202649 patent demonstrates that bispecific antibodies against OX40/CTLA-4 have anti-tumor activity against colon, pancreatic and bladder cancer, and that there is a synergistic action with anti-PD-1 antibodies for the treatment of colon cancer. However, there is no evidence to conclude that bispecific antibodies can be used in cancers other than colon, pancreas and bladder. Likewise, the patent only describes the application in combinatorial therapy with anti-PD-1 antibodies, without presenting data relative to the combination with other immunotherapeutic agents against other checkpoint targets.
- Published
- 2019
- Full Text
- View/download PDF
33. Cancer immunotherapy using anti-TIM3/PD-1 bispecific antibody: a patent evaluation of EP3356411A1.
- Author
-
Herrera-Camacho I, Anaya-Ruiz M, Perez-Santos M, Millán-Pérez Peña L, Bandala C, and Landeta G
- Subjects
- Animals, Antibodies, Bispecific immunology, Hepatitis A Virus Cellular Receptor 2 immunology, Humans, Neoplasms immunology, Patents as Topic, Programmed Cell Death 1 Receptor immunology, Antibodies, Bispecific administration & dosage, Immunotherapy methods, Neoplasms therapy
- Abstract
Introduction : TIM3 and PD-1 are checkpoint inhibitors in cancer that coordinate the downregulation of the proliferation of antigen-specific lymphocytes. There is a great need to discover and develop new therapies focused on inhibiting the action of TIM3 and PD-1 and consequently improving the immune response in the various types of cancer. The authors of patent EP3356411A1 propose several anti-TIM3/anti-PD-1 bispecific antibodies, as well as the method for producing them and their pharmacological application in the treatment of cancer. Areas covered : Patent EP3356411A1 describes a method by producing anti-TIM3/anti-PD-1 bispecific antibodies and their potential in cancer treatment. Expert opinion : Data supporting the patent demonstrate the ability by producing anti-TIM3/anti-PD-1 bispecific antibodies. Although the proposed methodology is very interesting and promising, further studies are necessary to assess the clinical applicability of the inventions on cancer.
- Published
- 2019
- Full Text
- View/download PDF
34. Cancer combinatorial immunotherapy using anti-OX40 agonist and anti-PD-L1 antagonist: a patent evaluation of US2018256711A1.
- Author
-
Perez-Santos M, Anaya-Ruiz M, Herrera-Camacho I, and Millán-Pérez Peña L
- Subjects
- Animals, Antibodies administration & dosage, Antibodies immunology, Humans, Immunotherapy adverse effects, Immunotherapy methods, Neoplasms immunology, Neoplasms pathology, Patents as Topic, Treatment Outcome, B7-H1 Antigen antagonists & inhibitors, Neoplasms therapy, Receptors, OX40 agonists
- Abstract
Introduction : OX40 is checkpoint inhibitor in cancer that coordinates the downregulation of the proliferation of antigen-specific lymphocytes. There is a great need to discover and develop new therapies focused on inhibiting the action of OX40 and consequently improving the immune response in the various types of cancer. Authors of patent US2018256711A1 propose a method to eradicate cancer that utilizes anti-OX40 agonist antibody in combination with anti-PD-L1 antagonist antibody. Areas covered : Patent US2018256711A1 describes a method of cancer combinatorial treatment consisting of the utilization of a pharmaceutical cocktail containing anti-OX40 and an anti-PD-L1 antibody. Expert opinion : The results of the clinical trials only support trials regarding the tolerability of combinatorial therapy, even when the objectives of determining the safety and pharmacokinetics of the treatment are proposed.
- Published
- 2019
- Full Text
- View/download PDF
35. Treatment of cancer with a combination of LAG-3Ig and anti-PD-1/anti-PD-L1 antibodies: a patent evaluation of US2018271940 A1.
- Author
-
Perez-Santos M, Anaya-Ruiz M, Cebada J, and Herrera-Camacho I
- Subjects
- Animals, Antibodies immunology, Antigens, CD immunology, B7-H1 Antigen immunology, Humans, Neoplasms immunology, Patents as Topic, Programmed Cell Death 1 Receptor immunology, T-Lymphocytes immunology, Lymphocyte Activation Gene 3 Protein, Antibodies administration & dosage, Immunotherapy methods, Neoplasms therapy
- Abstract
Introduction: LAG-3 is checkpoint inhibitor in cancer that coordinates the down regulation of the proliferation of antigen-specific lymphocytes. There is a great need to discover and develop new therapies focused on inhibiting the action of LAG-3 and consequently improving the immune response in the various types of cancer. Authors of patent US2018271940 propose a method to eradicate cancer that utilizes the combination of LAG-3Ig and anti-PD-1 or anti-PD-L1 antibodies. Areas covered: Patent US2018271940 describes a method consisting of the utilization of either a pharmaceutical cocktail containing LAG-3Ig and an anti-PD-1 or anti-PD-L1 antibody for activation of T cells as a potential for the treatment of cancer. Expert opinion: Data supporting the patent demonstrate the ability of LAG-3Ig and PD-1/PD-L1 to be useful in T cells activation, in addition to the reports showing that LAG-3 and anti-PD-1 and PD-L1 antibodies are therapeutic agents against cancer. Although the proposed methodology is very interesting and promising, further studies are necessary to assess the clinical applicability of the inventions on cancer.
- Published
- 2019
- Full Text
- View/download PDF
36. Transcription of interferon stimulated genes in response to Porcine rubulavirus infection in vitro.
- Author
-
Flores-Ocelotl Mdel R, Rosas-Murrieta NH, Vallejo-Ruiz V, Reyes-Leyva J, Herrera-Camacho I, and Santos-López G
- Abstract
Porcine rubulavirus (PoRV) is an emerging virus causing meningo-encephalitis and reproductive failures in pigs. Little is known about the pathogenesis and immune evasion of this virus; therefore research on the mechanisms underlying tissue damage during infection is essential. To explore these mechanisms, the effect of PoRV on the transcription of interferon (IFN) pathway members was analyzed in vitro by semi-quantitative RT-PCR. Ten TCID50 of PoRV stimulated transcription of IFNα, IFNβ, STAT1, STAT2, p48 and OAS genes in neuroblastoma cells, whereas infection with 100 TCID50 did not stimulate transcription levels more than non-infected cells. When the cells were primed with IFNα, infection with 1 TCDI50 of PoRV sufficed to stimulate the transcription of the same genes, but 10 and 100 TCID50 did not modify the transcription level of those genes as compared with non-infected and primed controls. MxA gene transcription was observed only when the cells were primed with IFNα and stimulated with 10 TCID50, whereas 100 TCID50 of PoRV did not modify the MxA transcription level as compared to non-infected and primed cells. Our results show that PoRV replication at low titers stimulates the expression of IFN-responsive genes in neuroblastoma cells, and suggest that replication of PoRV at higher titers inhibits the transcription of several members of the IFN pathway. These findings may contribute to the understanding of the pathogenesis of PoRV.
- Published
- 2011
- Full Text
- View/download PDF
37. [Biological characterization of three natural isolates of the porcine rubulavirus (Mexico)].
- Author
-
Borraz-Argüello Mdel T, Santos-López G, Vallejo-Ruiz V, Herrera-Camacho I, and Reyes-Leyva J
- Subjects
- Animals, HN Protein metabolism, Hemagglutination, Viral, Mexico, Neuraminidase metabolism, Rubulavirus enzymology, Rubulavirus genetics, Rubulavirus pathogenicity, Swine, Rubulavirus isolation & purification, Rubulavirus Infections virology, Swine Diseases virology
- Abstract
Biological characterization of three natural isolates of the porcine rubulavirus (Mexico). Porcine rubulavirus (PoRV) produces a neurological and reproductive syndrome in pigs called the blue-eye disease, known only from Mexico. Several isolates were grouped by the main symptoms presented during outbreaks: a) neurotropic in piglets, (b) broadly neurotropic in piglets and gonadotropic in adults, and (c) gonadotropic in adults. We studied some biological properties of three strains, which fall in one of each virus group: La Piedad Michoacán (LPM) and Producci6n Animal Cerdos 1 (PAC1) and 3 (PAC3), respectively. The analyzed viral properties are mainly related with the trans-membrane hemagglutinin-neuraminidase (HN) and fusion (F) proteins, such as cytopathic effect, hemolysis, hemagglutinating (HA) and neuraminidase (NA) activities. In the infection assays PAC1 strain presented the highest fusogenicity level; however, the most cytolytic strain was PAC3. In addition, HA and NA activities and viral genome of PAC3 strain was detected in supernatants during cell infection earlier than in the other two strains, which shows that PAC3 virions release from the host cell earlier than LPM and PAC1. Experimental determination in purified viruses shows that PAC3 presented a higher HA and NA activities; however, PAC1 shows other interesting properties, such as a high thermostability of HN and differences about substrate profile respect to LPM and PAC3. Our data suggest that NA activity is associated with the virulence of RVP.
- Published
- 2008
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.